Beacon Capital Partners
Alan Koder has a diverse work experience in the life sciences industry. Alan is currently the Managing Director of Life Science at Beacon Capital Partners since September 2021. Prior to that, they served as a Senior Director of Life Sciences at CBRE from May 2019 to September 2021. Alan also worked at Johnson & Johnson from April 2013 to May 2019, where they held the position of Director of Operations at Johnson & Johnson Innovation, JLABS. Before joining Johnson & Johnson, they were the Operations and EH&S Manager at Ambrx from 2004 to 2012. Alan's earlier roles include Senior Research Associate at the Genomics Institute of the Novartis Research Foundation from 2002 to 2004, Research Associate at Egea Biosciences from 2000 to 2002, and Research Assistant at the Salk Institute for Biological Studies from 1998 to 2000.
Alan Koder has a Bachelor of Science (B.Sc.) degree in Biochemistry and Cell Biology from UC San Diego. Alan also holds a Master of Business Administration degree from the University of San Diego, where they focused on Leadership, Real Estate, Finance, and Supply Chain. No specific start or end years were provided for either degree.
Beacon Capital Partners
Beacon Capital Partners is a tenant-focused private real estate investment firm with a 75-year legacy of successful real estate development, ownership and management. Beacon invests in high-quality office and life science properties in core markets with highly-educated workforces. Beacon has refined a proprietary investment sourcing model and developed a robust operating platform to transform properties into distinctive workplaces that attract today's tenants. This hands-on approach transforms properties through innovative design, state-of-the-art connectivity, modern amenities, and award-winning sustainability and risk management initiatives. From Fortune 100 firms to the leading innovative and growth companies, Beacon’s tenants are proud to call its distinctive workplaces home. Beacon is headquartered in Boston with offices in Chicago, Los Angeles, Denver, New York, San Francisco, Seattle, and Washington, D.C. Beacon has raised nine investment vehicles as well as multiple joint ventures and co-investments totaling over $19 billion in equity since 1998 from a diverse investor group including endowments, foundations, public, private and foreign pension funds, financial institutions, and sovereign wealth funds. This equity has fueled over 190 office and life science investments with a projected total value of $44 billion (including leverage and JV partner equity). Through its funds and joint ventures, Beacon currently owns approximately 25 million square feet of office properties either under management or development.